A retrospective study of risk factors of Mucormycosis in COVID-19 patients at a dedicated COVID hospital

Simple item page
dc.contributor.authorJoshi, PKen_US
dc.contributor.authorJadhav, KK.en_US
dc.date.accessioned2023-06-27T06:38:33Z
dc.date.available2023-06-27T06:38:33Z
dc.date.issued2022-09
dc.description.abstractBackground: In the present scenario treating Mucormycosis is proving more challenging than COVID-19. Aim and Objectives: To describe the demographic profile, clinical presentations, and risk factors of COVID-19 associated Mucormycosis. Materials and Methods: A retrospective cross-sectional study was conducted in 30 patients. Diagnosed cases of Mucormycosis with a history of RTPCR or Rapid antigen positive for COVID infection were included in the study. Patients with a past history of Mucormycosis infection or patients not admitted in the hospital were excluded. The study began after obtaining the Institutional Ethical Committee Approval. The statistical analysis was done to study the Percentage distribution of the risk factors. Results: About 66.66% patients were male and 33.33% were females. The age of the patients was 52.8 � 10.3 years. About 76.66% patients were farmers/farm workers. 90% of cases had Maxillary, 25 % Ethmoid and 5% had Sphenoid sinus involved. 23.33% were known diabetic. About 63.33% were having uncontrolled blood glucose level. About 23.33% were known hypertensive. About 66.66% had received steroids, 56.66% required oxygen therapy. 36.66% required Intensive care unit (ICU) and 6.66% required ventilator support during their management of acute COVID infection. None were fully vaccinated for COVID-19. Conclusion: The males are more susceptible to post-COVID 19 Mucormycosis infection as compared to females. Farmers/farm workers are at an increased risk too. Over use of steroids, uncontrolled blood sugar levels, oxygen therapy, long hospital stay, and ICU procedures and ventilators also contribute to the increased occurrence of post-COVID Mucormycosis. Most important factor that was observed was all the patients suffering from post-COVID Mucormycosis were not vaccinated.en_US
dc.identifier.affiliationsDepartment of Physiology, Dr. Vasantrao Pawar Medical College, Hospital and Research Center, Nashik, Maharashtra, Indiaen_US
dc.identifier.citationJoshi PK, Jadhav KK.. A retrospective study of risk factors of Mucormycosis in COVID-19 patients at a dedicated COVID hospital. National Journal of Physiology, Pharmacy and Pharmacology. 2022 Sept; 12(9): 1393-1398en_US
dc.identifier.issn2231-3206
dc.identifier.issn2320-4672
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/217697
dc.languageenen_US
dc.publisherMrs Dipika Charan of MedScience (India) Publicationsen_US
dc.relation.issuenumber9en_US
dc.relation.volume12en_US
dc.source.urihttps://dx.doi.org/10.5455/njppp.2022.12.01030202217012022en_US
dc.subjectCOVID-19en_US
dc.subjectRisk Factorsen_US
dc.subjectMucormycosisen_US
dc.subjectRetrospective Studyen_US
dc.titleA retrospective study of risk factors of Mucormycosis in COVID-19 patients at a dedicated COVID hospitalen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
NJPPP2022v12n9p1393.pdf
Size:
312.44 KB
Format:
Adobe Portable Document Format
Download
Collections
National Journal of Physiology, Pharmacy and Pharmacology